Hypothesis: anti-TIF1-gamma plus dysphagia and cutaneous ulceration will outperform myositis subtype alone for detecting cancer-associated myositis within 12 months

Claim In adult idiopathic inflammatory myopathy, a clinical rule that combines anti-TIF1-gamma positivity, dysphagia, cutaneous ulceration, and early disease onset will identify cancer-associated myositis within 12 months more accurately than myositis subtype alone.
Why this is plausible Cancer-associated myositis is enriched in dermatomyositis, particularly when anti-TIF1-gamma is present. Dysphagia and cutaneous ulceration are practical bedside red flags that often travel with high-risk phenotypes. Subtype alone is too coarse; a layered model should therefore improve discrimination and calibration.
Testable design
- Prospective multicenter cohort of adults with new or recent IIM
- Compare a subtype-only model against a layered model using anti-TIF1-gamma, dysphagia, ulceration, age, and time from onset
- Primary endpoint: incident cancer detected within 12 months
- Secondary endpoints: calibration slope, decision-curve net benefit, and screening efficiency
Falsification criteria The hypothesis is weakened if subtype alone performs equivalently after adjustment, or if the added clinical/serologic variables do not improve calibration and net benefit.
References
- Oldroyd AGS, Callen JP, Chinoy H, et al. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative. Nat Rev Rheumatol. 2023;19:805-817. DOI: 10.1038/s41584-023-01045-w
- Kim YK, Pyo JY, Kim JY, et al. The SCRIM score: a clinical tool for cancer risk-stratification in patients with idiopathic inflammatory myopathy. Arthritis Res Ther. 2025;27:204. DOI: 10.1186/s13075-025-03666-w
- De Vooght J, Vulsteke JB, De Haes P, et al. Anti-TIF1-gamma autoantibodies: warning lights of a tumour autoantigen. Rheumatology (Oxford). 2020;59(3):469-477. DOI: 10.1093/rheumatology/kez572